Likewise, combination of the anti-PD-L1 monoclonal antibody atezolizumab with the BRAF-/MEK-inhibitors vemurafenib and cobimetinib (and the combination of spartalizumab plus dabrafenib and trametinib alike) can provide a small incremental benefit; however, this comes at the cost of increased toxicity in patients with BRAF V600-mutant melanoma [11,12]. This evidence concerns the gene BRAF and melanoma.